Doctors Note Logo

Published on: 9/14/2026

Can Farxiga cause dangerous dehydration or kidney failure in seniors?

Farxiga (dapagliflozin) increases urine output, so it can lead to dehydration, low blood pressure, dizziness, and, in some cases, acute kidney injury, with seniors facing higher risk, particularly those also taking diuretics, ACE inhibitors, ARBs, or NSAIDs, or those who are eating and drinking less during illness. At the same time, this medication is proven to slow long-term kidney decline, and a small early dip in kidney function on lab work is often expected rather than harmful. Warning signs worth urgent attention include lightheadedness on standing, very dark or minimal urine, confusion, rapid weight loss, or swelling paired with fatigue. There are several important distinctions between temporary volume depletion and true kidney failure, along with hydration and sick-day guidance, so see below for the complete answer before making any decisions about your dose.

Because dehydration, medication side effects, infection, and kidney problems can produce nearly identical symptoms in older adults, guessing is risky and waiting can allow a reversible issue to become serious. A free, instant, online symptom check can help you organize what you are feeling, understand which explanations fit best, and decide whether this warrants a same-day call to your prescriber or emergency care.

Last reviewed for medical accuracy: 09/14/2025

answer background

Explanation

Can Farxiga cause dangerous dehydration or kidney failure in seniors?

Farxiga (dapagliflozin) is a commonly prescribed SGLT2 inhibitor used to help control blood sugar in type 2 diabetes, and to reduce the risk of hospitalization for heart failure. Because it increases the kidneys’ excretion of glucose—and with it, extra water—some people worry that Farxiga might lead to dehydration or even kidney injury, especially in older adults. Below, we’ll look at why these risks exist, what the data show, and practical steps seniors can take to stay safe.

How Farxiga works
Farxiga blocks a protein (SGLT2) in the kidney that normally reabsorbs glucose back into the blood. With that protein inhibited:

  • More glucose leaves the body in urine
  • Water follows the glucose (osmotic diuresis)
  • You may urinate more often and in larger volumes

This “diuretic-like” effect can help lower blood sugar and reduce blood volume (which may benefit heart failure), but it also means you lose extra fluid.

Why seniors face higher risks
As we age, a few factors make dehydration and kidney stress more likely:

  • Thirst perception often declines, so you may not feel thirsty until you’re already low on fluids.
  • Kidney function naturally decreases over time, reducing reserve capacity.
  • Many seniors take blood pressure medicines or diuretics that further lower blood volume.
  • Chronic conditions (arthritis, dementia, neuropathy) can limit access to water or the ability to respond to thirst.

Signs of dehydration to watch for
Left unaddressed, dehydration can lead to dizziness, low blood pressure, falls—and in extreme cases, acute kidney injury (AKI). Common warning signs include:

  • Dark yellow or strong-smelling urine
  • Dry mouth, lips and eyes
  • Feeling lightheaded, dizzy or weak
  • Rapid heartbeat or breathing
  • Confusion or feeling unusually sleepy

How Farxiga can affect the kidneys
Most people tolerate Farxiga without serious kidney issues. In fact, clinical trials have shown long-term kidney protection in patients with chronic kidney disease. However, if you become markedly dehydrated or your blood pressure drops too low, the kidneys may receive less blood flow, increasing the risk of AKI.

Key points on kidney effects:

  • An initial small decline in estimated glomerular filtration rate (eGFR) is expected in the first few weeks on Farxiga. This usually stabilizes.
  • Severe volume depletion—if not corrected—can tip that decline into AKI.
  • Reported AKI cases in real-world use are rare but tend to involve additional risk factors (e.g., concurrent diuretics, NSAIDs, vomiting/diarrhea).

What the data say

  • In large trials (e.g., DECLARE-TIMI 58, DAPA-CKD), rates of AKI were no higher—or were actually lower—in patients taking dapagliflozin versus placebo.
  • Post-marketing reports to the FDA identified isolated cases of AKI and dehydration, most in people with other triggers (severe illness, low fluid intake, or other kidney-impacting medications).
  • Observational studies often note a small risk of volume depletion events, especially in older adults on multiple blood pressure medicines.

Who is at greatest risk?
While most seniors on Farxiga do fine, watch extra carefully if you have any of these factors:
• Age over 75
• Already low blood pressure or orthostatic hypotension (“standing up dizziness”)
• Chronic kidney disease (eGFR < 60 mL/min/1.73 m²)
• Use of loop diuretics (furosemide, bumetanide) or thiazide diuretics
• Recent vomiting, diarrhea or inability to eat/drink
• Heart failure with reduced ejection fraction
• Use of NSAIDs (ibuprofen, naproxen) or other kidney-stress drugs

Steps to prevent dehydration and protect your kidneys

  1. Stay hydrated
    • Aim for 6–8 cups (1.5–2 L) of fluids daily, unless your doctor advises otherwise.
    • Include water, herbal teas, broths or electrolyte drinks, especially if you spend time outdoors or in heat.
  2. Monitor blood pressure and weight
    • Check first thing in the morning and again at bedtime.
    • A sudden drop in blood pressure or weight loss (>2 lbs/1 kg in 1–2 days) can signal volume changes.
  3. Check kidney function regularly
    • Your doctor will order periodic blood tests (serum creatinine, eGFR).
    • Report any unusual fatigue, swelling, or changes in urination.
  4. Adjust other medications as needed
    • Your prescriber may lower doses of diuretics or blood pressure meds when starting Farxiga.
    • Avoid NSAIDs as much as possible.
  5. Recognize early warning signs
    • Keep a simple log of symptoms: dizziness, thirst, urine color.
    • If you feel “off,” pause strenuous activity, sit or lie down, and sip fluids.

When to seek medical attention
If you experience any of the following, reach out to your healthcare provider right away. You may also try a free, online symptom check, using the doctor approved Ubie Symptom Checker.

  • Persistent dizziness or fainting spells
  • Very little or no urine output for 8 hours
  • Severe confusion, extreme fatigue or sudden weakness
  • Rapid heartbeat, rapid breathing or chest discomfort
  • Continuous vomiting, diarrhea or inability to keep fluids down

Bottom line
Farxiga helps many seniors manage diabetes and heart failure safely. It does carry a risk of dehydration and, if that is severe enough, possible acute kidney injury. However, with reasonable precautions—staying hydrated, monitoring blood pressure and kidney tests, adjusting other medications—the risk remains low.

Always speak to a doctor about anything that could be life threatening or serious. If you have concerns about Farxiga, dehydration or your kidney health, schedule an appointment to review your medications and labs. Your healthcare team can tailor recommendations for your individual needs.

(References)

  • * Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, Mann JFE, McMurray JJV, Lindberg M, Rossing P, Sjöström CD, Toto RD, Langkilde AM, Wheeler DC, DAPA-CKD Trial Committees and Investigators. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436-1446. doi: 10.1056/NEJMoa2024816. Epub 2020 Sep 24. PMID: 32970396.

  • * Wheeler DC, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Toto RD, Sjöström CD, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021 Jan;9(1):22-31. doi: 10.1016/S2213-8587(20)30369-7. PMID: 33338413.

  • * Wheeler DC, Toto RD, Stefánsson BV, Jongs N, Chertow GM, Greene T, Hou FF, McMurray JJV, Pecoits-Filho R, Correa-Rotter R, Rossing P, Sjöström CD, Umanath K, Langkilde AM, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016/j.kint.2021.03.033. Epub 2021 Apr 18. PMID: 33878338.

  • * Chertow GM, Vart P, Jongs N, Toto RD, Gorriz JL, Hou FF, McMurray JJV, Correa-Rotter R, Rossing P, Sjöström CD, Stefánsson BV, Langkilde AM, Wheeler DC, Heerspink HJL, DAPA-CKD Trial Committees and Investigators. Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease. J Am Soc Nephrol. 2021 Sep;32(9):2352-2361. doi: 10.1681/ASN.2021020167. Epub 2021 Jul 16. PMID: 34272327; PMCID: PMC8729835.

  • * Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-Wide Screening for Chronic Kidney Disease : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 Jun;176(6):788-797. doi: 10.7326/M22-3228. Epub 2023 May 23. PMID: 37216661; PMCID: PMC11091494.

  • * Koshino A, Schechter M, Chertow GM, Vart P, Jongs N, Toto RD, Rossing P, Correa-Rotter R, McMurray JJV, Górriz JL, Isidto R, Kashihara N, Langkilde AM, Wheeler DC, Heerspink HJL. Dapagliflozin and Anemia in Patients with Chronic Kidney Disease. NEJM Evid. 2023 Jun;2(6):EVIDoa2300049. doi: 10.1056/EVIDoa2300049. Epub 2023 May 19. PMID: 38320128.

  • * Heerspink HJ, Provenzano M, Vart P, Jongs N, Correa-Rotter R, Rossing P, Mark PB, Pecoits-Filho R, McMurray JJ, Langkilde AM, Wheeler DC, Toto RB, Chertow GM. Dapagliflozin and Blood Pressure in Patients with Chronic Kidney Disease and Albuminuria. Am Heart J. 2024 Apr;270:125-135. doi: 10.1016/j.ahj.2024.02.006. Epub 2024 Feb 15. PMID: 38367893.

  • * Hu H, Li W, Hao Y, Peng Z, Zou Z, Wei J, Zhou Y, Liang W, Cao Y. The SGLT2 inhibitor dapagliflozin ameliorates renal fibrosis in hyperuricemic nephropathy. Cell Rep Med. 2024 Aug 20;5(8):101690. doi: 10.1016/j.xcrm.2024.101690. PMID: 39168099; PMCID: PMC11384938.

  • * Boeckhaus J, Gale DP, Simon J, Ding J, Zhang Y, Bergmann C, Turner AN, Hall M, Sayer JA, Srivastava S, Kang HG, Cerkauskaite-Kerpauskiene A, Gillion V, Claes KJ, Krueger B, de Fallois J, Walden U, Choi M, Schueler M, Mueller RU, Todorova P, Hohenstein B, Zeisberg M, Friede T, Knebelmann B, Halbritter J, Gross O. SGLT2-Inhibition in Patients With Alport Syndrome. Kidney Int Rep. 2024 Dec;9(12):3490-3500. doi: 10.1016/j.ekir.2024.09.014. Epub 2024 Sep 24. PMID: 39698346; PMCID: PMC11652101.

  • * Nakao Y, Mori M, Mori Y, Bonventre JV. SGLT2 inhibitors and acute kidney injury. Nephrol Dial Transplant. 2026 Jan 30;41(2):243-254. doi: 10.1093/ndt/gfaf132. PMID: 40736512; PMCID: PMC12855603.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.